As such, the goals of this study were to evaluate the efficacy of E-selectin/AAV2/2 (E-sel/AAV2/2), a novel gene construct for therapeutic angiogenesis, for improving limb salvage, reperfusion, and function in a clinically relevant murine gangrene model. The gene discussed is SELE; the disease is gangrene.